Search alternatives:
larger decrease » marked decrease (Expand Search)
mapk decrease » marked decrease (Expand Search), small decrease (Expand Search), mean decrease (Expand Search)
nn decrease » a decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
larger decrease » marked decrease (Expand Search)
mapk decrease » marked decrease (Expand Search), small decrease (Expand Search), mean decrease (Expand Search)
nn decrease » a decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
Table 2_SLC4A10 impedes atherosclerosis by diminishing IFN-γ/GZMB levels of CD8+ T cells via the MAPK pathway.docx
Published 2025“…</p>Conclusions<p>These data demonstrate that SLC4A10 mitigates cytotoxicity by decreasing the levels of IFN-γ/GZMB of SLC4A10<sup>+</sup> CD8<sup>+</sup> T cells via the MAPK pathway, which impedes plaque progression and aids stabilization.…”
-
17
Image 1_SLC4A10 impedes atherosclerosis by diminishing IFN-γ/GZMB levels of CD8+ T cells via the MAPK pathway.pdf
Published 2025“…</p>Conclusions<p>These data demonstrate that SLC4A10 mitigates cytotoxicity by decreasing the levels of IFN-γ/GZMB of SLC4A10<sup>+</sup> CD8<sup>+</sup> T cells via the MAPK pathway, which impedes plaque progression and aids stabilization.…”
-
18
Table 1_SLC4A10 impedes atherosclerosis by diminishing IFN-γ/GZMB levels of CD8+ T cells via the MAPK pathway.docx
Published 2025“…</p>Conclusions<p>These data demonstrate that SLC4A10 mitigates cytotoxicity by decreasing the levels of IFN-γ/GZMB of SLC4A10<sup>+</sup> CD8<sup>+</sup> T cells via the MAPK pathway, which impedes plaque progression and aids stabilization.…”
-
19
Data Sheet 1_SLC4A10 impedes atherosclerosis by diminishing IFN-γ/GZMB levels of CD8+ T cells via the MAPK pathway.zip
Published 2025“…</p>Conclusions<p>These data demonstrate that SLC4A10 mitigates cytotoxicity by decreasing the levels of IFN-γ/GZMB of SLC4A10<sup>+</sup> CD8<sup>+</sup> T cells via the MAPK pathway, which impedes plaque progression and aids stabilization.…”
-
20